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Background and aim: Spondyloarthritis (SpA) is a disease that normally affects the axial 
skeleton. It progressively leads to overall stiffness up to severe postural deformity of rachis and 
functional impotence. The objective of the study was to quantify, through an economic model, 
the impact of specialized testing and pharmacological treatments carried out by the National 
Health Service (NHS) in normal clinical practice, before the patient is diagnosed with SpA in 
Italy. In line with the analysis objective, the chosen perspective is that of the NHS.
Method: The study was conducted by analyzing the Health Search Database – IMS Health 
Longitudinal Patient Database, from which newly diagnosed SpA patients were identified over the 
period 1 January 2007 to 31 December 2013. The use of specialist health care services and phar-
macological treatments provided to the patients before the final SpA diagnosis were estimated.
Results: Through a retrospective analysis of the Health Search Database, 1,084 subjects (aged 
25–45 years) were identified. These patients produced an expense of approximately €153,000 
in the 3 years prior to a confirmed SpA diagnosis, in terms of specialist check-ups and drugs, 
presumably not appropriately used due to a lack of diagnosis. If we assume that the Health Search 
Database is a representative sample of the Italian population, it may be estimated that, in the 
3 years prior to SpA diagnosis, over €5.4 million was largely unduly spent in Italy to examine 
and manage 38,232 newly diagnosed SpA patients, between 2010 and 2013.
Conclusion: The costs due to the delay in SpA diagnosis were quantified for the first time in 
Italy. For this reason, this work represents a contribution for national and regional decision mak-
ers to understand the current clinical practice and the economic consequences of a diagnostic 
delay in the short and medium term.
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Introduction
Spondyloarthritis (SpA) is a disease that normally affects the axial skeleton. It progres-
sively leads to overall stiffness up to severe postural deformity of rachis and functional 
impotence. SpA also includes psoriatic arthritis, arthritis associated with inflammatory 
bowel disease, and reactive arthritis. The term SpA covers both patients who have 
already developed structural damage in the sacroiliac joints or spine visible on radio-
graphs (radiographic axial SpA, also termed ankylosing spondylitis [AS]) and patients 
without such structural damage, labeled as non-radiographic SpA.  The disease usually 
starts in the third decade of life with a male to female ratio of two to one for radio-
graphic SpA and of one to one for non-radiographic SpA. More than 90%  heritability 
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has been estimated, the highest genetic association being 
with HLA-B27.  Patients present with chronic back pain and 
stiffness predominantly of the pelvis and the lower back, but 
any part of the spine can be involved. A typical symptom is 
inflammatory back pain, which is clinically defined. Patients 
complain of morning stiffness mostly of the lower back with 
improvement on exercise but not by rest. They can also be 
awakened by back pain in the night, typically in the second 
part of the night. Several clinical indices (presence of chronic 
back pain starting at an age ≤45 years, inflammatory back 
pain, peripheral and extra-articular manifestations, response 
of symptoms to non-steroidal anti-inflammatory drugs 
[NSAIDs], family history of SpA and related disorders), 
and several laboratory indices (HLA-B27 and acute phase 
reactants testing, and imaging findings) have to be combined 
for classification and diagnosis of SpA.  The development of 
new criteria for classification and for screening of patients 
with axial SpA have been crucial for the early identification 
and treatment of such patients, with magnetic resonance 
imaging being the most important existing imaging method.
The reported prevalence of SpA is between 0.32% and 
1.4% in different surveys.1,2 According to the ethnic group 
and the diagnostic criteria used, prevalence of AS ranges 
between 0.06% and 0.2%.1,2 Its incidence is approximately 
6–7 patients in 100,000 adults per year.3 This disease causes 
high use of health services, reduced productivity, and a lim-
ited working capacity in the patients.4 
SpA has a significant impact on the patient’s life, espe-
cially in terms of quality of life. Literature data indicate that 
the patients are subject to different physical constraints, 
causing limited working capacity and affecting social rela-
tionships and family life. From an economic point of view, 
the main cost factor is represented by the reduced physical 
functions.5 
In terms of economic burden, many studies demonstrated 
that SpA (mainly AS) causes high social and medical costs.5–14 
Indirect costs linked to the days of absence from work – 
together with the loss of related productivity – are the most 
important determinant of total costs.7,8
This can partially explain the association between total 
costs and disease severity. A recent revision by Palla et al4 
summarizes the estimated direct and indirect costs in differ-
ent countries.
As of today, the economic burden of SpA in Italy is not 
directly known, but some studies estimated that the annual 
social cost incurred for AS patients treated with biological 
drugs accounts for approximately €20 million in Italy. These 
patients represent only 22% of the diagnosed ones.15,16
Diagnostic delay is one of the key clinical challenges of 
SpA.17 The average time span from the symptom onset to the 
definitive diagnosis is 8–10 years.17 This diagnostic delay has 
a negative impact not only on the patient, but potentially, also 
on the disease progression and on the directly related costs 
incurred by National Health Service (NHS) and society as 
a whole (indirect costs). The delayed diagnosis causes delay 
in management and in potential advantages derived from 
the slowdown of the disability and the improvement of the 
quality of life.
A  delay in diagnosis of 8.57 years was estimated in the 
UK population, causing loss of spine mobility and inability 
to work in working-age patients.18 NSAIDs and blockers of 
cytokines TNF-α and IL-17 are effective therapies. Early 
treatment with NSAIDs, as well as a diagnosis within 4 
years from the disease onset in patients starting an anti-TNF 
therapy, may reduce the progression of the radiographic dam-
age. Anti-TNF therapy gives a better response if the duration 
of the disease symptoms is shorter than 10 years.18 The main 
reason for the delay in diagnosis is due to the fact that spinal 
pain is an extremely common condition and, in most cases, 
it is not due to severe causes. Furthermore, old diagnostic 
criteria require significant radiographic lesions, normally 
arising at a later stage, while routine laboratory tests often 
supply results in the range for this kind of disease. Conversely, 
the new diagnostic criteria available today should allow an 
earlier diagnosis of SpA patients.19
The objective of the study was to quantify, through an 
economic model, the impact of specialized testing and phar-
macological treatments carried out by the NHS in normal 
clinical practice, before the patient is diagnosed with SpA in 
Italy. In line with the analysis objective, the chosen perspec-
tive is that of the NHS.
Methods
The study was conducted by analyzing the HSD, from which 
newly diagnosed SpA patients were identified over the period 
1 January 2007 to 31 December 2013. The use of specialist 
health care services and pharmacological treatments provided 
to the patients before the final SpA diagnosis were estimated.
Data sources
Data were processed through a descriptive inquiry of the 
HSD, created by the Italian Society of General Medicine and 
Primary Care in 1998.20 The database includes a wide and 
representative sample of the Italian population and is aimed 
at collecting information derived from the daily clinical 
practice of general practitioners (GPs).
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GPs are selected so as to include a proportional number 
of patients to the population size of the respective geographi-
cal areas. When this study was conducted, Health Search 
contained information of over 900 Italian practitioners, and 
a total sample of more than 1.5 million patients.
According to the selection criteria used by the Health 
Search network researchers, the population represented in 
the database is distributed by sex and age, in line with the 
general Italian adult population of ISTAT data.21
The information collected by each GP is representative of 
the daily clinical practice and contains demographic and clini-
cal information (i.e., diagnoses, laboratory tests with results, 
hospitalizations, etc.), drug prescriptions, prevention data 
(i.e., blood pressure, body mass index, smoking, etc.). These 
data are associated with an identification code of the patient, 
according to the classical criteria of a relational database.
Furthermore, a lot of this information is directly codified 
according to the standards commonly used by the NHS for 
reimbursements, applying the national health care range of 
fees. For each single drug a pharmaceutical database reports 
the Anatomical Therapeutic Chemical  classification (ATC 
code), the molecule, the trade name, and the MINSAN code 
(the code assigned by the Health Ministry to each specific 
drug when placed on the market).
Enrollment criteria
First, the population to be included in the economic analysis 
was identified. Specifically, within the database, the patients 
with at least an SpA diagnosis were identified (code ICD-9 
720: “Ankylosing spondylitis and other inflammatory spon-
dylopathies”) over the period 1 January 2010 to 31 December 
2013. This code includes the following subgroups of diseases:
•	 720.0 “Ankylosing spondylitis”;
•	 720.1 “Spinal enthesopathy”;
•	 720.2 “Unclassified sacro-iliitis”;
•	 720.8 “Other inflammatory spondylopathies”;
•	 720.9 “Unspecified inflammatory spondylopathy”.
Among the SpA-diagnosed subjects, only the patients who 
had received a confirmed diagnosis (by the GP with 720 
diagnosis code) during the following year were selected. 
Finally, in order to identify only the newly diagnosed patients, 
the subjects who had used health care services due to SpA 
in the previous 3 years were excluded.
Therefore, all the newly diagnosed SpA patients during 
the year were selected.
The economic analysis was based only on the patients 
aged 25–45 years, in order to consider an age group that 
actually included newly diagnosed SpA patients. The selec-
tion process of the population being considered is reported 
in Figure 1.
Economic analysis
Based on the selected population, all specialist and phar-
maceutical services correlating with potential symptoms 
or manifestations of SpA that took place in the 3 years 
prior to the first SpA diagnosis were considered, in order 
to quantify the amount and type of health care services 
provided before the real diagnosis. In particular, accord-
ing to the clinical expert opinion of two rheumatologists, 
co-authors of this study, the SpA-specific health care ser-
vices that could have allowed an early diagnosis of SpA 
(Supplementary material) were selected. In order to have a 
conservative analysis, only services strictly related to SpA 
diagnosis were considered.
The economic quantification of specialist services was 
carried out matching the reimbursement fee of the national 
health care range of fees22 to each service and adding up 
the costs incurred by each patient in the period of analysis. 
Figure 1 Selection criteria for new SpA patients aged 25–45 years.
Abbreviation: SpA, spondyloarthritis. 
1 January 2007
No diagnosis in the previous 3 years Confirmed diagnosis in the following year
1 January 2010
Cost determination Enrollment period Follow-up
Period of analysis observation
31 December 2013
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The same procedure was carried out for pharmaceutical 
prescriptions, taking into account the prices available in 
the pharmaceutical manual associated with each AIC code 
being analyzed (code of marketing authorization issued by 
the Italian Medicines Agency).23
In order to obtain a reliable quantification of the expense 
incurred for these services nationally, the economic model 
assumed that the analyzed population is a representative 
sample of the national population. Therefore, an inference 
analysis was carried out, adjusting the services and related 
costs to the total resident population in Italy in the same 
period of analysis.
Ethical statement 
Ethical approval was not required due to the Health Search 
IMS Health Longitudinal Patient Database (HSD) being a 
longitudinal primary care medical record database that was 
set up by members of the Italian College of General Prac-
titioners (SIMG). The HSD contains anonymized clinical 
data (diagnoses, patient referrals, hospital admissions, and 
clinical investigations’ results) and prescription data (drug 
name, prescription date, number of days’ supply given) for 
all the medications which are reimbursed by the Italian NHS, 
and is available to researchers on request.
Results
In the total population of the Health Search sample, 6,461 in 
1,549,417 subjects received at least an SpA diagnosis over 
the considered period of analysis. Of these, 3,142 patients 
(48.6%) were excluded due to the lack of diagnosis by the 
GP in the following year. An additional 958 patients were 
excluded because they were already diagnosed as having SpA 
in the 3 years prior to the index date. Finally, the patients’ 
extraction in the reference age group was 1,084 subjects, 
corresponding to an incidence of 2.2 per 1,000 in the 25–45 
year old population of the analyzed sample.
Figure 2 shows the method used to identify the objective 
population, while Table 1 indicates the characteristics of the 
extracted subjects.
The drug consumption of the 1,084 considered patients 
during the 3 years of survey amounts to €27,260 in total 
(Table 2). The most used drugs are glucocorticoids, propi-
onic and acetic acid derivatives, and related substances. The 
number of specialist services accounts for 4,005 in total. 
ICD-9
720
6,461 patients with at least a
diagnosis during the
considered period
1 January 2010 to
31 December 2013
3,142 excluded patients due
to the lack of a confirmed
diagnosis in the year after the
first diagnosis
3,142 patients with confirmed
diagnosis in the year after the
first diagnosis
2,361 new patients (no
diagnosis in the 3 years prior
to the first diagnosis) 
1,084 new
patients aged
25–45 years
Figure 2 Selection process of new SpA patients.
Abbreviations: ICD-9, International Statistical Classification of the Diseases and Related Health Problems, version 9; SpA, spondyloarthritis.
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Table 1 Characteristics of enrolled patients aged 25–45 years 
and related diagnoses
Clinical characteristics Patients (n) %
Age (mean) 43.32
Sex   
Male 381 35.1%
Female 703 64.9%
Geographic distribution*   
North East 313 28.9%
North West 290 26.8%
Centre 161 14.9%
South – Islands 290 26.8%
Charlson Index   
0–1 983 90.7%
2–3 91 8.4%
≥4 10 0.9%
SpA-related diagnoses Diagnosis (n) %
Peripheral enthesopathy and allied 
syndromes
248 12.4%
Psoriasis and related conditions 56 2.8%
Regional enteritis, Crohn’s disease, 
granulomatous enteritis
11 0.6%
Ulcerative colitis 9 0.5%
Note: *The geographic origin of 30 patients is missing.
Abbreviation: SpA, spondyloarthritis. 
Table 2 Drug and specialist service expense of 1,084 patients 
aged 25–45 years related to the 3 years prior to first diagnosis
ATC code Drug 
description
Patients Drug box 
consumption
Total 
expense
M01AH Coxib 164 389 €6,010
H02AB Glucocorticoids 581 1377 €4,873
M01AE Propionic acid 
derivatives
578 968 €4,722
M03BX Other centrally 
acting muscle 
relaxant drugs 
240 310 €3,799
M01AB Acetic acid 
derivatives and 
related substances
485 919 €3,471
M02AA Topical non-
steroidal anti-
inflammatories
131 149 €1,762
M01AX Other non-
steroidal anti-
inflammatory/
antirheumatic 
drugs
202 511 €1,733
M01AC Oxicam 
derivatives
99 182 €860
H02BX Corticosteroids 
for systemic use
5 7 €31
Total – 4,812 €27,260
Specialist service Patients Number of 
services
Total 
expense
Magnetic resonance diagnostic 263 356 €41,971
Specialist check-up 1,012 1,700 €34,445
Laboratory 493 1,095 €16,293
X-ray diagnostic 534 629 €14,230
Related diagnostic 86 123 €9,823
Scintigraphy diagnostic 28 36 €7,126
Ultrasound diagnostic 47 57 €1,532
Physiotherapy 7 9 €87
Total – 4,005 €125,507
Total expense €152,767
More than half of these correspond to specialist check-ups 
and laboratory tests, with a total expense of €125,507.
More broadly, it is estimated that in the 3 years prior to an 
SpA diagnosis, each patient is provided with four specialist 
health care services and four boxes of drugs related to undi-
agnosed SpA, with a total expense of €140.9.
Assuming that the Health Search database provides a 
representative sample of the Italian population and an infer-
ence analysis can be carried out, it may be estimated that in 
Italy, in the 3 years prior to an SpA diagnosis, an expense of 
over €5.4 million was incurred to examine and treat 38,232 
new patients between 2010 and 2013 (Table 3).
Discussion
SpA is a disabling disease preventing patients from living a 
normal life. Early diagnosis and adequate treatment may slow 
the disease progression down and improve the patient’s health 
conditions and quality of life in the short and long term. The 
timespan between the disease onset and the diagnosis is 
mainly due to difficult early diagnosis of SpA.17,18
For the first time in Italy, this work attempted to quantify 
the impact of the diagnostic delay, both in terms of services 
provided and costs incurred by the NHS. Through a retrospec-
tive analysis of the Health Search database, 1,084 subjects 
(aged 25–45 years) were identified. These patients produced 
an expense of approximately €153,000 in the 3 years prior to 
a confirmed SpA diagnosis, in terms of specialist  check-ups 
Table 3 Inferential analysis on the Italian resident population 
aged 25–45 years between 2010 and 2012
Data referred to 
3 years prior to 
the analysis
General 
population (aged 
25–45 years)
SpA 
patients
Cost of 
services 
and drugs
HS sample 500,842 1,084 €152,767
Inference on the 
Italian population
17,664,275a 38,232 €5,387,972
Note: aMean of resident Italian population 2010–2014.24
Abbreviation: SpA, spondyloarthritis.
and drugs, presumably not appropriately used due to a 
missing diagnosis. According to our assumptions, this cost 
represents the economic impact produced by the missed SpA 
diagnoses that might have been reduced if a correct and early 
SpA diagnostic procedure had been applied.
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If we assume that the Health Search database is a 
representative sample of the Italian population, it may be 
estimated that, in the 3 years prior to the SpA diagnosis, 
over €5.4 million were unduly spent in Italy to examine 
and manage 38,232 newly diagnosed SpA patients, between 
2010 and 2013. The GP plays a key role and should be urged 
to promptly investigate suspected SpA-related back pain. In 
specific cases – patient’s young age, inflammatory pain, often 
at night, alternating sciatica, family history, and concomitant 
diseases like psoriasis, uveitis, dactylitis, enthesitis – the GP 
should refer the patient to a rheumatologist.
Like all retrospective analyses on sample data in this 
field, this study has methodological limits. The first limit 
is the nature of the Health Search database. In fact, from 
a general medicine standpoint, it is possible that the diag-
nosis is not reported on time or the patient’s diagnostic 
workup is not completed by the GP but by a specialist. In 
fact, of the 6,461 patients with at least an SpA diagnosis 
in the analyzed period, approximately 48% were not con-
firmed the diagnosis the following year.  This may be due 
to a false diagnosis or to the fact that the patient is followed 
by a specialist and the GP has lost track of the patient. In 
both cases this study underestimates the real impact of the 
health expense.
The second limit to the analysis is linked to the identifica-
tion of SpA patients and to the inclusion criteria. Specifically, 
the diagnosis code considered in the analysis was ICD-9 720 
“Ankylosing spondylitis and other inflammatory spondylopa-
thies.” In effect, this code represents a generic value that may 
also include diagnoses not specifically related to SpA, such as 
spinal enthesopathy (720.1), unclassified sacroiliitis (720.2) 
or other inflammatory spondylopathies (720.8). However, if 
“ankylosing spondylitis” had been associated only with code 
720.2, it would have caused an extreme loss of information 
due to the missed compilation of the complete code by the 
GP. In fact, over 80% of the ICD 9 codes considered did not 
have a complete codification up to the fourth digit. This also 
causes incidence estimates to be much higher than reported 
in the literature.3
Finally, it should be considered that the expense 
obtained by the analysis is underestimated, as it only 
includes the direct costs for specialist and pharmaceutical 
services. These costs, calculated at rate, should be added 
to those related to disabilities and irreversible lesions due 
to diagnostic delay, in addition to the costs due to the loss 
of productivity.25,26
In conclusion, the costs due to the delay in SpA diagnosis 
were quantified for the first time in Italy. For this reason, 
this work represents a contribution for national and regional 
decision makers to understand the current clinical practice 
and economic consequences of a diagnostic delay in the short 
and medium term.
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